Abstract

In Germany, the recently approved 20-valent pneumococcal conjugate vaccine had a substantially higher coverage against pneumonia in adults than the 13-valent vaccine, while the coverage gap compared to the 23-valent polysaccharide vaccine was small https://bit.ly/3q4skov

Original languageEnglish
JournalEuropean Respiratory Journal
Volume59
Issue number2
ISSN0903-1936
DOIs
Publication statusPublished - 01.02.2022

Funding

(CM-COVID). This study was supported by an unrestricted grant from Pfizer. Teva, and research funding from Actelion, Bayer Health Care, Biotest, partly supported by a grant of the Federal Ministry of Education and Research

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany'. Together they form a unique fingerprint.

Cite this